{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:49:54Z","timestamp":1790660994299,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Laboratoires Fournier"},{"name":"National Health and Medical Research Council of Australia"},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["457103"],"award-info":[{"award-number":["457103"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["1024105"],"award-info":[{"award-number":["1024105"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["1037786"],"award-info":[{"award-number":["1037786"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["1137071"],"award-info":[{"award-number":["1137071"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["2018537"],"award-info":[{"award-number":["2018537"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FIELD study"},{"name":"FIELD trial"},{"DOI":"10.13039\/501100001030","name":"National Heart Foundation of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000971","name":"Diabetes Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000971","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Diabetes New Zealand"},{"DOI":"10.13039\/501100008415","name":"Finnish Diabetes Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008415","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FIELD study Management Committee"},{"name":"NHMRC Practitioner Fellowship","award":["1121272"],"award-info":[{"award-number":["1121272"]}]},{"name":"Sydney Medical School Foundation Fellowship"},{"name":"NHMRC Program","award":["1105467"],"award-info":[{"award-number":["1105467"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Haptoglobin (HP) 2-2 phenotype has been suggested as a risk factor for cardiovascular disease (CVD) and to modulate fenofibrate benefit on CVD risk in Type 2 diabetes. However, little is known as to whether HP levels modulate CVD risk and fenofibrate response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Haptoglobin phenotype and levels were determined in 8047 Fenofibrate Intervention and Event Lowering in Diabetes trial participants at baseline and randomization (after a 16\u2005week run-in period, including a 6\u2005week fenofibrate therapy) and their association with new on-trial total CVD events over 5 years was assessed. Higher baseline HP levels were associated with total CVD events in the placebo group {n = 4030, hazard ratio [95% confidence interval (CI)] = 1.30 [1.02\u20131.66] for HP level Tertile 3 vs. Tertile 1, P = 0.035}. This was driven by participants with HP 1-1 phenotype (P for interaction = 0.011). Participants with the lowest baseline HP level tertile and HP 1-1 phenotype tended to have the lowest CVD risk, whereas CVD risk was similar in other participants, regardless of HP phenotype and levels. Fenofibrate benefit on total CVD events did not differ significantly by HP phenotypes, baseline HP level tertiles, or tertiles of change in HP levels by fenofibrate during active run-in.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Higher baseline HP levels were associated with a higher CVD risk, especially in participants with HP 1-1 phenotype. A lower CVD risk is found only in Type 2 diabetes participants with both the HP 1-1 phenotype and low baseline HP levels. Fenofibrate benefits on CVD risk reduction did not differ by HP levels or phenotype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lay summary<\/jats:title>\n                    <jats:p>We evaluated the relationship of different forms or phenotypes of the blood protein, haptoglobin, and its circulating levels with the risk of developing CVD and fenofibrate benefit in patients with Type 2 diabetes, and showed that both HP phenotype and levels are important to assess CVD risk in patients with Type 2 diabetes, although fenofibrate did not modulate CVD risk via HP phenotype or level.Higher baseline HP levels were associated with higher CVD risk, especially in participants with HP 1-1 phenotype.Fenofibrate benefit on CVD did not differ by HP phenotype and baseline or change in HP levels.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwaf562","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T11:35:29Z","timestamp":1757417729000},"page":"132-142","source":"Crossref","is-referenced-by-count":2,"title":["The association of haptoglobin levels and phenotype with cardiovascular disease in Type 2 diabetes: a Fenofibrate Intervention and Event Lowering in Diabetes sub-study"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7229-7614","authenticated-orcid":false,"given":"Kwok Leung","family":"Ong","sequence":"first","affiliation":[{"name":"NHMRC Clinical Trials Centre, The University of Sydney , Level 6, Medical Foundation Building, 92\u201394 Parramatta Road, Sydney, NSW 2050 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0995-4524","authenticated-orcid":false,"given":"Andrzej S","family":"Januszewski","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, The University of Sydney , Level 6, Medical Foundation Building, 92\u201394 Parramatta Road, Sydney, NSW 2050 ,","place":["Australia"]},{"name":"Sydney Pharmacy School, The University of Sydney , Sydney, NSW 2050 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1106-4118","authenticated-orcid":false,"given":"Habib","family":"Francis","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, The University of Sydney , Level 6, Medical Foundation Building, 92\u201394 Parramatta Road, Sydney, NSW 2050 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8593-9767","authenticated-orcid":false,"given":"Rachel L","family":"O\u2019Connell","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, The University of Sydney , Level 6, Medical Foundation Building, 92\u201394 Parramatta Road, Sydney, NSW 2050 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8715-9908","authenticated-orcid":false,"given":"Abubakar","family":"Mangani","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, The University of Sydney , Level 6, Medical Foundation Building, 92\u201394 Parramatta Road, Sydney, NSW 2050 ,","place":["Australia"]},{"name":"Sydney Pharmacy School, The University of Sydney , Sydney, NSW 2050 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1440-4829","authenticated-orcid":false,"given":"Liping","family":"Li","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, The University of Sydney , Level 6, Medical Foundation Building, 92\u201394 Parramatta Road, Sydney, NSW 2050 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8718-6175","authenticated-orcid":false,"given":"Peter G","family":"Colman","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Royal Melbourne Hospital , Parkville, VIC 3050 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3085-5627","authenticated-orcid":false,"given":"David R","family":"Sullivan","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, The University of Sydney , Level 6, Medical Foundation Building, 92\u201394 Parramatta Road, Sydney, NSW 2050 ,","place":["Australia"]},{"name":"Department of Chemical Pathology, Royal Prince Alfred Hospital , Sydney, NSW 2050 ,","place":["Australia"]},{"name":"School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney , Sydney, NSW 2050 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5239-9274","authenticated-orcid":false,"given":"James D","family":"Best","sequence":"additional","affiliation":[{"name":"Lee Kong Chian School of Medicine, Nanyang Technological University ,","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2107-6480","authenticated-orcid":false,"given":"Russell S","family":"Scott","sequence":"additional","affiliation":[{"name":"Christchurch Hospital and NZ Clinical Research Ltd , 264 Antigua Street, Christchurch 8011 ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0583-3717","authenticated-orcid":false,"given":"Alicia J","family":"Jenkins","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, The University of Sydney , Level 6, Medical Foundation Building, 92\u201394 Parramatta Road, Sydney, NSW 2050 ,","place":["Australia"]},{"name":"Diabetes and Vascular Medicine Laboratory, Baker Heart and Diabetes Institute , Melbourne, VIC 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9426-9136","authenticated-orcid":false,"given":"Anthony C","family":"Keech","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, The University of Sydney , Level 6, Medical Foundation Building, 92\u201394 Parramatta Road, Sydney, NSW 2050 ,","place":["Australia"]},{"name":"Department of Cardiology, Royal Prince Alfred Hospital , Sydney, NSW 2050 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"2026010607170539200_zwaf562-B1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2337\/diaclin.34.3.148","article-title":"Role of haptoglobin in health and disease: a focus on diabetes","volume":"34","author":"MacKellar","year":"2016","journal-title":"Clin Diabetes"},{"key":"2026010607170539200_zwaf562-B2","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1001\/jama.1980.03300450023014","article-title":"The predictive value of serum haptoglobin in hemolytic disease","volume":"243","author":"Marchand","year":"1980","journal-title":"JAMA"},{"key":"2026010607170539200_zwaf562-B3","doi-asserted-by":"crossref","first-page":"100851","DOI":"10.1016\/j.mam.2020.100851","article-title":"Haptoglobin: from hemoglobin scavenging to human health","volume":"73","author":"di Masi","year":"2020","journal-title":"Mol Aspects Med"},{"key":"2026010607170539200_zwaf562-B4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1161\/ATVBAHA.107.153965","article-title":"Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial","volume":"28","author":"Milman","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026010607170539200_zwaf562-B5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2337\/dc21-1429","article-title":"Haptoglobin phenotype modifies the effect of fenofibrate on risk of coronary event: ACCORD lipid trial","volume":"45","author":"Warren","year":"2022","journal-title":"Diabetes Care"},{"key":"2026010607170539200_zwaf562-B6","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1111\/jdi.14290","article-title":"Haptoglobin phenotype and levels in type 2 diabetes and effects of fenofibrate","volume":"15","author":"Januszewski","year":"2024","journal-title":"J Diabetes Investig"},{"key":"2026010607170539200_zwaf562-B7","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"2026010607170539200_zwaf562-B8","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/S0140-6736(09)60698-X","article-title":"Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial","volume":"373","author":"Rajamani","year":"2009","journal-title":"Lancet"},{"key":"2026010607170539200_zwaf562-B9","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00125-014-3458-7","article-title":"The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study","volume":"58","author":"Ong","year":"2015","journal-title":"Diabetologia"},{"key":"2026010607170539200_zwaf562-B10","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s00125-015-3652-2","article-title":"Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study","volume":"58","author":"Ong","year":"2015","journal-title":"Diabetologia"},{"key":"2026010607170539200_zwaf562-B11","doi-asserted-by":"crossref","first-page":"112080","DOI":"10.1016\/j.diabres.2025.112080","article-title":"Relationship of haptoglobin phenotype and levels with sight-threatening diabetic retinopathy in type 2 diabetes: a Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) substudy","volume":"222","author":"Ong","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"2026010607170539200_zwaf562-B12","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1515\/cclm-2013-0018","article-title":"An enzyme linked immunosorbent assay (ELISA) for the determination of the human haptoglobin phenotype","volume":"51","author":"Levy","year":"2013","journal-title":"Clin Chem Lab Med"},{"key":"2026010607170539200_zwaf562-B13","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1210\/jc.2019-00723","article-title":"Haptoglobin phenotype modulates lipoprotein-associated risk for preeclampsia in women with type 1 diabetes","volume":"104","author":"Kelly","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026010607170539200_zwaf562-B14","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026010607170539200_zwaf562-B15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2337\/dc14-0180","article-title":"Serum 25-hydroxyvitamin D: a predictor of macrovascular and microvascular complications in patients with type 2 diabetes","volume":"38","author":"Herrmann","year":"2015","journal-title":"Diabetes Care"},{"key":"2026010607170539200_zwaf562-B16","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.metabol.2015.12.008","article-title":"Opposite associations between alanine aminotransferase and \u03b3-glutamyl transferase levels and all-cause mortality in type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"65","author":"Williams","year":"2016","journal-title":"Metabolism"},{"key":"2026010607170539200_zwaf562-B17","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1007\/s00125-010-1806-9","article-title":"Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes","volume":"53","author":"Taskinen","year":"2010","journal-title":"Diabetologia"},{"key":"2026010607170539200_zwaf562-B18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jclinepi.2021.01.008","article-title":"Framework for the treatment and reporting of missing data in observational studies: the treatment and reporting of missing data in observational studies framework","volume":"134","author":"Lee","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"2026010607170539200_zwaf562-B19","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0735-1097(02)02534-2","article-title":"Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the Strong Heart Study","volume":"40","author":"Levy","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026010607170539200_zwaf562-B20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1475-2840-12-31","article-title":"Genetic analysis of haptoglobin polymorphisms with cardiovascular disease and type 2 diabetes in the Diabetes Heart Study","volume":"12","author":"Adams","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"2026010607170539200_zwaf562-B21","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jacc.2012.09.063","article-title":"Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin","volume":"61","author":"Cahill","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026010607170539200_zwaf562-B22","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.jacc.2015.07.076","article-title":"The risk of coronary heart disease associated with glycosylated hemoglobin of 6.5% or greater is pronounced in the haptoglobin 2-2 genotype","volume":"66","author":"Cahill","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026010607170539200_zwaf562-B23","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.cca.2009.12.025","article-title":"The haptoglobin 2-2 genotype is associated with carotid atherosclerosis in 64-year old women with established diabetes","volume":"411","author":"Ryndel","year":"2010","journal-title":"Clin Chim Acta"},{"key":"2026010607170539200_zwaf562-B24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/1479164116645247","article-title":"The haptoglobin 2-2 genotype is associated with inflammation and carotid artery intima-media thickness","volume":"13","author":"Dalan","year":"2016","journal-title":"Diab Vasc Dis Res"},{"key":"2026010607170539200_zwaf562-B25","doi-asserted-by":"crossref","first-page":"e000732","DOI":"10.1161\/JAHA.113.000732","article-title":"Haptoglobin 2-2 genotype is not associated with cardiovascular risk in subjects with elevated glycohemoglobin-results from the Bruneck Study","volume":"3","author":"Pechlaner","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"2026010607170539200_zwaf562-B26","first-page":"99","article-title":"Haptoglobin levels are influenced by Hp1-Hp2 polymorphism, obesity, inflammation, and hypertension in type 2 diabetes mellitus","volume":"66","author":"Rodrigues","year":"2019","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"key":"2026010607170539200_zwaf562-B27","doi-asserted-by":"crossref","first-page":"e76817","DOI":"10.1371\/journal.pone.0076817","article-title":"Plasma haptoglobin concentrations are elevated in patients with coronary artery disease","volume":"8","author":"Lee","year":"2013","journal-title":"PLoS One"},{"key":"2026010607170539200_zwaf562-B28","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000487648","article-title":"Elevated plasma haptoglobin level as a potential marker for poor prognosis in acute cerebral infarction","volume":"79","author":"Zhang","year":"2018","journal-title":"Eur Neurol"},{"key":"2026010607170539200_zwaf562-B29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1741-7007-7-87","article-title":"The obesity and inflammatory marker haptoglobin attracts monocytes via interaction with chemokine (C-C motif) receptor 2 (CCR2)","volume":"7","author":"Maffei","year":"2009","journal-title":"BMC Biol"},{"key":"2026010607170539200_zwaf562-B30","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1161\/CIRCRESAHA.107.149435","article-title":"Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability","volume":"101","author":"Levy","year":"2007","journal-title":"Circ Res"},{"key":"2026010607170539200_zwaf562-B31","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jacc.2019.11.051","article-title":"Haptoglobin phenotype modifies the influence of intensive glycemic control on cardiovascular outcomes","volume":"75","author":"Carew","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026010607170539200_zwaf562-B32","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2337\/dc23-2165","article-title":"Haptoglobin phenotype and intensive glycemic control for coronary artery disease risk reduction in people with type 2 diabetes: the ADVANCE study","volume":"47","author":"Cahill","year":"2024","journal-title":"Diabetes Care"},{"key":"2026010607170539200_zwaf562-B33","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwae175.326","article-title":"Does the relationship between time-varying achieved HbA1c and risk of coronary events depend on haptoglobin phenotype within the Action for Health in Diabetes (Look AHEAD) study?","volume":"31","author":"Carew","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026010607170539200_zwaf562-B34","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s12933-024-02448-z","article-title":"The relationship between repeated measurements of HbA1c and risk of coronary events among the common haptoglobin phenotype groups: the Action for Health in Diabetes (Look AHEAD) study","volume":"23","author":"Carew","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2026010607170539200_zwaf562-B35","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s00125-007-0751-8","article-title":"Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus","volume":"50","author":"Hiukka","year":"2007","journal-title":"Diabetologia"},{"key":"2026010607170539200_zwaf562-B36","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.2337\/dc07-0015","article-title":"Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome","volume":"30","author":"Rosenson","year":"2007","journal-title":"Diabetes Care"},{"key":"2026010607170539200_zwaf562-B37","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/j.orcp.2011.03.012","article-title":"Fenofibrate ameliorates insulin resistance, hypertension and novel oxidative stress markers in patients with metabolic syndrome","volume":"5","author":"Ueno","year":"2011","journal-title":"Obes Res Clin Pract"},{"key":"2026010607170539200_zwaf562-B38","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1161\/HYPERTENSIONAHA.112.203661","article-title":"Fenofibrate improves vascular endothelial function by reducing oxidative stress while increasing endothelial nitric oxide synthase in healthy normolipidemic older adults","volume":"60","author":"Walker","year":"2012","journal-title":"Hypertension"},{"key":"2026010607170539200_zwaf562-B39","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1751-553X.2007.00898.x","article-title":"Haptoglobin: a review of the major allele frequencies worldwide and their association with diseases","volume":"29","author":"Carter","year":"2007","journal-title":"Int J Lab Hematol"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwaf562\/64276781\/zwaf562.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/1\/132\/64276781\/zwaf562.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/1\/132\/64276781\/zwaf562.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:17:20Z","timestamp":1767701840000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/33\/1\/132\/8254748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,9,11]]},"published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwaf562","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,9,11]]}}}